Update 3/25/21 (News out today) Actinium Announces Completion of Enrollment of Second Dose Cohort in Actimab-A Venetoclax Combination Trial for Patients with R/R AML
Excerpt from today’s PR: “With clinical experience in nearly 150 patients, robust IP and a clinically validated supply chain, we are leaders in the rapidly growing field of targeted alpha radiotherapy and specifically Actinium-225.”
Analysts and Institutions Exhibit High Expectations for Actinium (ATNM) and for Good Reason
“Vanguard and Blackrock lead a group of 42 institutional investors that own 22% of the company shares”
ATNM has a long cash runway estimated at over one year.
Good day everyone,
Today we are continuing coverage of, Actinium Pharmaceuticals, Inc. (NYSE: ATNM), a clinical stage biopharmaceutical company.
Current price $8.30 per share
These are exciting times for those who have followed ATNM with us. While the Phase 3 SIERRA trial for lomab-B relating to bone marrow transplants has been exciting, and is nearing full enrollment, the company is moving toward other opportunities as well.
Earlier this month, the company appointed Mr. Mark Kubik to the position of Chief Business Officer. Mr. Kubik joins Actinium with over 25 years of experience in transformative and award-winning Business Development and M&A transactions.
The appointment of Mr. Kubik is a significant development at ATNM, both as to the potential for lomab-B and AWE technology, as well as the potential for an exit. What does ATNM have that could make it an acquisition target?
Actinium’s AWE technology platform is used to produce ARCs or Antibody Radiation Conjugates, a highly potent and selective form of targeted radiotherapy. Through their AWE technology platform, they can utilize multiple radioisotopes to match the needs of the desired indication.
ATNM is the leader in the application of Actinium-225 the potent alpha emitting radioisotope. Actinium-225 is the most powerful medical grade radioisotope known to man.
These are proprietary and patented technologies that could be utilized by pharma companies to advance their own ARCs while gaining exclusivity to lomab-B and Actinium-225 technology.
This could be the perfect time to look at ATNM. The company is being recognized by its peers and its technology is attracting collaborations. We believe the upcoming presentation at the annual AACR meeting, on April 10th, may be a catalyst for the company.
As a part of your due diligence, we urge you to explore the ATNM website where you will find more detailed and technical information than we can put in this report.
ATNM has developed into a biopharma company with tremendous potential. Though many investors are familiar with ATNM, many are not. The niche that ATNM participates in is highly technical and is generally a precursor treatment for other curative compounds. All of that could change in the near term as ATNM brings more catalysts to the forefront.
4 Wall Street analysts have issued ratings and price targets for Actinium Pharmaceuticals in the last 12 months. Their average twelve-month price target is $45.00, predicting that the stock has a possible upside of 440.87%. The high price target for ATNM is $65.00 and the low-price target for ATNM is $25.00. There are currently 4 buy ratings for the stock, resulting in a consensus rating of “Buy.”
ATNM shares are trading 56% below their 52-week high. Vanguard and Blackrock lead a group of 42 institutional investors that own 22% of the company shares. HC Wainwright has a price target of $65 and some of the top institutional investor’s own shares. These are professionals that may see the end game for ATNM.
Tiny float
Proprietary, patented technology
Liabilities ($877K)
Late-stage clinical trial
High institutional ownership
Long term cash runway (est. over one year)
Chart setup indicates potential breakout.
ATNM has technology that is advanced, adaptable, and has tremendous potential either through business development or an exit.
Stay tuned and stay informed,
The Traders News Group
original report below
____________________
Big news out from Actinium this AM – Actinium Announces Initiation of Patient Enrollment in Iomab-ACT Trial for Targeted Conditioning Prior to CD19 CAR T-Cell Therapy
Mid-day update 3/24/21 Actinium Pharma (NYSE: ATNM)
Actinium (ATNM) Issues News That May Indicate a Huge Path Forward for its Proprietary lomab-B Therapy Beyond Bone Marrow Transplant
Good day everyone,
Today we are continuing coverage of, Actinium Pharmaceuticals, Inc. (NYSE: ATNM), a clinical stage biopharmaceutical company.
Current price $8.70 per share
ATNM came out with breaking news this morning:
Actinium Announces Initiation of Patient Enrollment in Iomab-ACT Trial for Targeted Conditioning Prior to CD19 CAR T-Cell Therapy
Actinium announced that its collaborator, Memorial Sloan Kettering Cancer Center (MSK), has commenced patient enrollment in the Phase 1 study evaluating Iomab-ACT for targeted conditioning prior to treatment with MSK’s CD19 targeted CAR T-cell 19-28z.
Iomab-ACT is a low dose version of Actinium’s Phase 3 drug candidate Iomab-B. The MSK study will utilize lomab-ACT for conditioning prior to CAR-T therapy, a T-Cell therapy developed by MSK.
Sandesh Seth, Actinium’s Chairman and CEO, said “This is a major milestone for Actinium, we intend to establish Iomab-ACT as the universal solution for targeted, non-chemotherapy conditioning, that harnesses the power of radiation. With Iomab-B nearing complete enrollment in the Phase 3 SIERRA trial for bone marrow transplant conditioning, starting to treat patients in this Iomab-ACT trial for CAR-T conditioning could not come at a better time. We look forward to continuing to build out our strategic business unit in targeted conditioning to best serve patients seeking potentially curative bone marrow transplant, adoptive cell therapy and gene therapy to improve patient access and outcomes.”
As science advances toward more cellular and genetic research to cure disease, lomab-B, in differing doses, is coming to the forefront as a measure to help control certain difficulties in clinical trials. The ATNM lomab-B and AWE technology is an excellent process to apply radiation in a non-invasive way.
We believe the growth of the market for lomab-B could be directly tied to advancements in cellular and genetic medicine, a booming sector right now.
As we said earlier, on April 10th, ATNM will be offering a poster presentation titled “Dose optimization and radiation dosimetry of CD45-targeting 225Actinium-armed antibody as a conditioning agent for adoptive cell therapy” at the American Association of Cancer Research (AACR 2021).
This poster presentation at the AACR may be the catalyst that opens many more doors for ATNM as oncology experts from everywhere learn specifics about the benefit of lomab-B in their curative endeavors.
ATNM offers a tiny float for rapid price movement, proprietary, patented science, a chart indicating a potential breakout, and the possibility of a short squeeze.
Stay tuned for our full report on ATNM.
The Traders News Group
original AM report below
___________________________________
Actinium (ATNM) and Their Proprietary Technology May Have A Great 2021
Gene therapy is an area of biotech that could out perform.
Short interest suggests ATNM could be our next squeeze play.
Good day everyone,
Today we are continuing coverage of, Actinium Pharmaceuticals, Inc. (NYSE: ATNM), a clinical stage biopharmaceutical company.
Current price $8.29 per share
Outstanding shares (est.) 15.43 million
Float (est.) 13.25 million shares
We last reported on ATNM in December 2020 and a lot has happened with the company since then. ATNM has some similarities to our last reported company, DLPN, as of pre-market now a 500% gainer, as to setup but they are in entirely different sectors. Tiny float, same level of short interest, breakout potential, and new technology.
Why we like ATNM shares at their current price:
Tiny float
Proprietary (patented) technology
Late-stage clinical trial
High institutional ownership
Long term cash runway
Chart setup indicates potential breakout
In late December, ATNM shares dropped almost 25% when an independent review of data for their SIERRA trial for lomab-B resulted in a recommendation to proceed with the trial to full enrollment. While the SIERRA trial has been hugely successful, investors were looking for different results.
On April 10th, ATNM will be offering a poster presentation titled “Dose optimization and radiation dosimetry of CD45-targeting 225Actinium-armed antibody as a conditioning agent for adoptive cell therapy” at the American Association of Cancer Research (AACR 2021).
As advances in cell and gene therapies address more disease indications and thus a larger overall patient population, the ATNM commitment to developing targeted conditioning agents to improve patient access to the these potentially curative therapies and patient outcomes grows stronger.
In 2018 ATNM and Astellas Pharma began a collaboration utilizing the ATNM AWE delivery system.
Builds the collaboration utilizing Actinium’s Antibody Warhead Enabling (AWE) Technology Platform with selected Astellas targeting agents.
The new look at the expansion of a targeted conditioning portfolio with next-generation Actinium-225-based CD45 targeting ARC, and the continued collaboration with Astellas.
As the company stock chart indicates, ATNM shares have been looking for traction since this year started. The time for ATNM to make a breakthrough may be now.
Positives of Gene Therapy
With its potential to eliminate and prevent hereditary diseases such as cystic fibrosis and hemophilia and its use as a possible cure for heart disease, AIDS, and cancer, gene therapy is a potential medical miracle-worker.
We will have more on ATNM soon,
The Traders News Group
Privacy Policy and Disclaimer
Your Consent
By using our site, you consent to our online privacy policy and disclaimer.
Do we disclose any information to outside parties?
We do not sell your information to anyone. Please see our cookie policy below.
https://tradersnewssource.com/cookie-policy-us/
What information do we collect?
We collect information from you when you subscribe to our newsletter or fill out a form on one of our social platforms. This includes your email address and or mobile phone number.
When registering on our site, as appropriate, you may be asked to enter your: e-mail address and or mobile number.
What do we use your information for?
When we collect your email or mobile number it is used for one purpose to send you the information you requested about small cap stocks. Please read our disclaimer carefully before viewing our emails.
Your information, whether public or private, will not be sold, exchanged, transferred, or given to any other company for any reason whatsoever, other than for the express purpose of delivering the information on small cap stocks that you requested.
We send periodic emails
The email address you provide may be used to send you information, the small acp stock reports you requested, respond to inquiries, and/or other requests or questions.
How do we protect your information?
We implement a variety of security measures to maintain the safety of your personal information when you enter, submit, your email address. We use secure third parties to send email and sms messages to you.
Because we value your privacy we have taken the necessary precautions to be in compliance with the California Online Privacy Protection Act.
Online Privacy Policy Policy
This online privacy policy applies to information collected through our website and social media platforms.
Contacting Us
If there are any questions regarding this privacy policy or disclaimer you may contact us using the information below.
Editor@TradersNewsSource.com
Traders News Source is a wholly owned subsidiary of Traders News Source LLC, herein referred to as TNS LLC.
Our reports/releases are a commercial advertisement and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our services, joining our site or our email/blog list as well as any social networking platforms we may use.
Please Note: TNS LLC and its employees are not a registered investment advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever.
Release of Liability: Through use of this website viewing or using you agree to hold TNS LLC, its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. TNS LLC encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and TNS LLC makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provide herein. Instead TNS LLC strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D. TNS LLC is compliant with the Can Spam Act of 2003. TNS LLC does not offer such advice or analysis, and TNS LLC further urges you to consult your own independent tax, business, financial and investment advisors. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled.
The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results.
In preparing this publication, TNS LLC has relied upon information supplied by its customers, publicly available information and press releases which it believes to be reliable; however, such reliability cannot be guaranteed. Investors should not rely on the information contained in this website. Rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. The owners and operators of this website have not been compensated for the mention of and do not hold any form of equity in fnko or dlpn. The owners and operators of this website have been compensated twenty two thousand five hundred dollars cash via bank wire for this week’s distributed opinions on atnm. The advertisements in this website are believed to be reliable, however, TNS LLC and its owners, affiliates, subsidiaries, officers, directors, representatives and agents disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of materials facts from such advertisement. TNS LLC is not responsible for any claims made by the companies advertised herein, nor is TNS LLC responsible for any other promotional firm, its program or its structure.
TNS LLC is not affiliated with any exchange, electronic quotation system, the Securities Exchange Commission or FINRA. TNS LLC is not a Broker/Dealer and does not engage in high frequency trading.
